An acute myeloid leukemia (AML) in which the blasts do not show evidence of myeloid differentiation by morphology and conventional cytochemistry. (WHO, 2001)
Comprehensive, easy-to-understand information about this condition
How we create this content →Documentation on acute myeloid leukemia with minimal differentiation is limited due to its rarity and the challenges in systematically studying such a specific subtype. Fewer than 20,000 cases of acute myeloid leukemia are diagnosed annually in the U.S., and AML M0 represents a small fraction of these cases. The lack of identified genetic markers and the variability in clinical presentation further complicate comprehensive characterization.
To navigate your journey with acute myeloid leukemia with minimal differentiation, seek out a hematologist or oncologist who specializes in acute leukemias, particularly those with experience in rare subtypes. Consider reaching out to resources like the National Organization for Rare Disorders (NORD) at rarediseases.org for additional support and information. While there are no specific patient organizations for AML M0, participating in general AML registries or natural history studies may provide valuable insights and contribute to research efforts.
Currently, there are several orphan drug designations for acute myeloid leukemia, including FDA-approved treatments such as Azacitidine, Gemtuzumab ozogamicin, and Venetoclax. Additionally, there are numerous drugs in development aimed at improving outcomes for patients with AML. However, no clinical trial data is available specifically for AML M0. For more information on ongoing research, you can search ClinicalTrials.gov for relevant studies on acute myeloid leukemia.
Actionable guidance for navigating care for acute myeloid leukemia with minimal differentiation
To navigate your journey with acute myeloid leukemia with minimal differentiation, seek out a hematologist or oncologist who specializes in acute leukemias, particularly those with experience in rare subtypes. Consider reaching out to resources like the National Organization for Rare Disorders (NORD) at rarediseases.org for additional support and information. While there are no specific patient organizations for AML M0, participating in general AML registries or natural history studies may provide valuable insights and contribute to research efforts.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation on acute myeloid leukemia with minimal differentiation is limited due to its rarity and the challenges in systematically studying such a specific subtype. Fewer than 20,000 cases of acute myeloid leukemia are diagnosed annually in the U.S., and AML M0 represents a small fraction of these cases. The lack of identified genetic markers and the variability in clinical presentation further complicate comprehensive characterization.
To navigate your journey with acute myeloid leukemia with minimal differentiation, seek out a hematologist or oncologist who specializes in acute leukemias, particularly those with experience in rare subtypes. Consider reaching out to resources like the National Organization for Rare Disorders (NORD) at rarediseases.org for additional support and information. While there are no specific patient organizations for AML M0, participating in general AML registries or natural history studies may provide valuable insights and contribute to research efforts.
Currently, there are several orphan drug designations for acute myeloid leukemia, including FDA-approved treatments such as Azacitidine, Gemtuzumab ozogamicin, and Venetoclax. Additionally, there are numerous drugs in development aimed at improving outcomes for patients with AML. However, no clinical trial data is available specifically for AML M0. For more information on ongoing research, you can search ClinicalTrials.gov for relevant studies on acute myeloid leukemia.
Actionable guidance for navigating care for acute myeloid leukemia with minimal differentiation
To navigate your journey with acute myeloid leukemia with minimal differentiation, seek out a hematologist or oncologist who specializes in acute leukemias, particularly those with experience in rare subtypes. Consider reaching out to resources like the National Organization for Rare Disorders (NORD) at rarediseases.org for additional support and information. While there are no specific patient organizations for AML M0, participating in general AML registries or natural history studies may provide valuable insights and contribute to research efforts.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation on acute myeloid leukemia with minimal differentiation is limited due to its rarity and the challenges in systematically studying such a specific subtype. Fewer than 20,000 cases of acute myeloid leukemia are diagnosed annually in the U.S., and AML M0 represents a small fraction of these cases. The lack of identified genetic markers and the variability in clinical presentation further complicate comprehensive characterization.
To navigate your journey with acute myeloid leukemia with minimal differentiation, seek out a hematologist or oncologist who specializes in acute leukemias, particularly those with experience in rare subtypes. Consider reaching out to resources like the National Organization for Rare Disorders (NORD) at rarediseases.org for additional support and information. While there are no specific patient organizations for AML M0, participating in general AML registries or natural history studies may provide valuable insights and contribute to research efforts.
Currently, there are several orphan drug designations for acute myeloid leukemia, including FDA-approved treatments such as Azacitidine, Gemtuzumab ozogamicin, and Venetoclax. Additionally, there are numerous drugs in development aimed at improving outcomes for patients with AML. However, no clinical trial data is available specifically for AML M0. For more information on ongoing research, you can search ClinicalTrials.gov for relevant studies on acute myeloid leukemia.
Actionable guidance for navigating care for acute myeloid leukemia with minimal differentiation
To navigate your journey with acute myeloid leukemia with minimal differentiation, seek out a hematologist or oncologist who specializes in acute leukemias, particularly those with experience in rare subtypes. Consider reaching out to resources like the National Organization for Rare Disorders (NORD) at rarediseases.org for additional support and information. While there are no specific patient organizations for AML M0, participating in general AML registries or natural history studies may provide valuable insights and contribute to research efforts.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 4 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.